Background: Neoplastic mast cells involving the bone marrow (BMMCs) of patients with mastocytosis display an aberrant expression of CD25 and/or CD2 antigens. The aim of this study was to determine the frequency of CD2 and CD25 expression on skin mast cells (sMCs) of patients with mastocytosis in the skin at the early stage of the disease. Furthermore, the usefulness of the phenotypic profile of sMCs for the diagnosis of systemic mastocytosis (SM) was evaluated. Methods: The 52 adults included in the study were diagnosed with mastocytosis strictly according to the criteria of the World Health Organization. CD117, CD2 and CD25 antigen expression on sMCs was detected by immunohistochemistry. The presence of the KIT D816V mutation in the BM was analyzed using allele-specific PCR. Results: The presence of CD2- or CD25-positive sMCs was detected in 57.1% of cutaneous mastocytosis (CM) and 90.3% of SM cases (p = 0.008). In all mastocytosis patients, CD2 expression on sMCs was more frequent than CD25 expression (67.3 and 38.5%, respectively). Moreover, CD2 expression on sMCs was more frequent in SM than in CM cases (p = 0.02). The presence of one of the aberrant sMC antigens was detected in 84.2% of patients with the KIT D816V mutation in the BM. A positive correlation between densities of CD25- and CD117-positive sMCs was found in SM patients (r = 0.46, p = 0.009). Conclusions: Although sMCs displayed immunoreactivity for one of the neoplastic antigens in the majority of SM patients, the aberrant CD2 and/or CD25 expression on sMCs is not as indicative of SM as the BMMC immunophenotype. i 2014 S. Karger AG, Basel

1.
Valent P, Aberer E, Beham-Schmid CH, et al: Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). Am J Blood Res 2013;3:174-180.
2.
Arock M, Valent P: Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010;3:497-516.
3.
Horny HP, Sotlar K, Valent P: Evaluation of mast cell activation syndromes: impact of pathology and immunohistology. Int Arch Allergy Immunol 2012;159:1-5.
4.
Pardanani A: CME Information: systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013;88:612-624.
5.
Horny HP, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, Valent P, Bain B: Mastocytosis; in Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Varderman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC, 2008, pp 54-63.
6.
Lange M, Nedoszytko B, GCrska A, yawrocki A, Sobjanek M, Koz"owski D: Mastocytosis in children and adults: clinical disease heterogeneity. Arch Med Sci 2012;8:533-541.
7.
Valent P, Akin C, Escribano L, et al: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-453.
8.
Lange M, Niedoszytko M, Renke J, Gle$ J, Nedoszytko B: Clinical aspects of paediatric mastocytosis; a review of 101 cases. J Eur Acad Dermatol Venereol 2013;27:97-102.
9.
Orfao A, Garcia-Montero A C, Sanchez L, Escribano L: Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30.
10.
Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bultmann B, Valent P, Horny HP: Variable presence of KIT D816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010;220:586-595.
11.
Valent P, Cerny-Reiterer S, Herrmann H, et al: Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol 2010;23:369-378.
12.
Georgin-Lavialle S, Lhermitte L, Baude C, et al: Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor. Blood 2011;118:5246-5249.
13.
Ghannadan M, Hauswirth AW, Schernthaner GH, et al: Detection of novel CD antigens on the surface of human mast cells and basophils. Int Arch Allergy Immunol 2002;127:299-307.
14.
Baumgartner C, Sonneck K, Krauth MT, et al: Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry. Eur J Clin Invest 2008;38:326-335.
15.
Sotlar K, Horny HP, Simonitsch I, et al: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-1325.
16.
Valent P, Sotlar K, Horny HP: Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymph 2011;52:740-744.
17.
Hollmann TJ, Brenn T, Hornick JL: CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis. Am J Surg Pathol 2008;32:139-145.
18.
Mirowski G, Austen KF, Chiang L, Horan RF, Sheffer AL, Weidner N, Murphy GF: Characterization of cellular dermal infiltrates in human cutaneous mastocytosis. Lab Invest 1990;63:52-62.
19.
Soilleux EJ: Recent advances in mastocytosis and neoplasms of probable monocytic/dendritic cell lineage. Diagn Histopathol 2010;16:182-205.
20.
Yang F, Tran TA, Carlson JA, His ED, Ross CW, Arber DA: Paraffin section immunophenotype of cutaneous and extracutaneous mast cell disease. Am J Surg Pathol 2000;24:703-709.
21.
Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al: Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010;125:719-726.
22.
Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, Valent P: Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001;25:529-536.
23.
Morgado JM, Sanchez-Munoz L, Teodosio CG, et al: Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive' alone is more informative than the ‘CD25 and/or CD2' WHO criterion. Mod Pathol 2012;25:516-521.
24.
Valent P, Akin C, Arock M, et al: Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012;157:215-225.
25.
Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, et al: Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011;24:1157-1168.
26.
Bodemer C, Hermine O, Palmerini F, et al: Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010;130:804-815.
27.
Kleewein K, Lang R, Diem A, et al: Diffuse cutaneous mastocytosis masquerading as epidermolysis bullosa. Pediatr Dermatol 2011;28:720-725.
28.
Schernthaner GH, Jordan JH, Ghannadan M, et al: Expression, epitope analysis and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001,98:3784-3792.
29.
Lim K-H, Tefferi A, Lasho TL, et al: Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009,113:5727-5736.
30.
Theodosio C, Garcia-Montero AC, Jara-Acevedo M, et al: An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012;26:951-958.
31.
Wasag B, Niedoszytko M, Piskorz A, Lange M, Renke J, Jassem E, Biernat W, Debiec-Rychter M, Limon J: Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 2011;39:859-865.
32.
Janssens AS, Heide R, den Hollander JC, Mulder PG, Tank B, Oranje AP: Mast cell distribution in normal adult skin. J Clin Pathol 2005;58:285-289.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.